Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 28
- 主要终点
- Time to Disease Progression (TDP)
研究概览
简要总结
This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data will be collected for approximately 24 months.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin
排除标准
- •Patients not willing or unable to signed written consent form
研究组 & 干预措施
Bevacizumab
Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
干预措施: Bevacizumab (Drug)
结局指标
主要结局
Time to Disease Progression (TDP)
时间窗: Up to a maximum of 36.4 months
Time to disease progression was defined as the time interval between first-line treatment onset and investigator-assessed disease progression. Disease progression was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
次要结局
- Treatment Duration: Number of Bevacizumab Cycles(Up to a maximum of 36.4 months)